http://www.firststagecapital.com
We are committed to delivering value to our clients. We offer effective and appropriate advice based on experience, not only of finance but also of founding companies and working with technology entrepreneurs. We know that successful relationships work on mutual trust and respect. We work in partnership with our clients to achieve their goals and we share alongside them in the risks and the rewards of success.
Next Century Technologies, Inc. (NCT) is a holding company with an international focus on medical technology, software, biotechnology and related distribution services and outsourcing services to those markets. Headquartered in Reston, Virginia, Next Century concentrates on a structure of lean management, investment in technology and autonomous operation of its individual investments which are developing new products and services that revolutionize the markets they address. NCT is affiliated with Zimmerman Adams International Ltd. (www.zimmint.com), a Nominated Advisor and Broker for the AIM and a member of the London Stock Exchange. ZAI has a unique investor base comprising Institutions that specifically invest in "foreign", i.e. non-UK shares, via the UK markets. Next Century has a close relationship with an extensive worldwide network of contacts to assist our portfolio of companies in rapidly building an international organization. Via its strength in these specific industries, we have the ability to identify and assist new companies developing leading edge products and services.
Cambridge Research BioVentures (CRB) is a technology investment fund established to support the early development of promising biomedical and life sciences discoveries. Research Corporation Technologies (RCT) of Tucson, Arizona has made £8 million available to the fund, to be invested exclusively in life science opportunities in the United Kingdom and Ireland. RCT is an independent technology management company that commercializes technologies from universities and research institutions throughout the world. RCT's commercialization vehicles include licensing, partnerships, seed investments and venture development of early-stage technologies. CRB is the first European extension of RCT's global 21st Century Venture Initiative. Through this program, a network of international partners finds and develops promising biomedical and life sciences inventions from research centers worldwide. There are now 21st Century Venture offices functioning across the USA and in Canada and Australia. Dr Chris Keightley is Managing Director of the CRB fund and will co-ordinate the investment activities of RCT through CRB. Scientists or inventors wishing to dicuss the commercialisation of novel technologies are welcome to contact CRB at the e-mail address below. For more information, please contact: Chris Keightley (Managing Director) Cambridge Research BioVentures St Michael's House St Michael's Longstanton Cambridge
The Skypoint team is a cohesive group with a history of working together for more than 15 years. We bring a range of experience in the following areas: Telecommunications and IT industry operations Product design - hardware and/or software Technology analysis Finance and intellectual property strategy Deal structuring and negotiations Through working with more than 80 telecom technology start-ups, our team has the collective expertise required to add significant value in making critical links between technology, application, production, support services and end customers. We also bring significant transaction experience, including 19 acquisitions and 18 IPOs with a combined value of approximately $3 billion.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory